The US Food and Drug Administration’s device center on 26 October published its annual list of guidance documents it will prioritize in fiscal 2022, including drafting guidances to help manufacturers transition COVID-19 emergency products to full marketing status and focus on digital health technologies.
As it does yearly, the FDA broke down its list of priority guidances by two tiers, A and B
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?